ABT-450, a New Regimen for Treating Hepatitis C Virus
ABT-450 is a promising new medication designed to treat chronic hepatitis C virus (HCV) infection. A recent study highlighted its effectiveness, revealing that over 95 percent of patients achieved a cure within just three months of treatment. This regimen, which is taken in pill form, was presented at a significant medical conference and has garnered attention due to the global impact of HCV, which affects approximately 184 million individuals worldwide and contributes to over 350,000 deaths annually from related liver diseases. Common side effects reported among patients included fatigue and headache, yet the overall response to the treatment has been encouraging. In June 2014, the U.S. Food and Drug Administration initiated a priority review for ABT-450, indicating a potential approval on the horizon. This development represents a significant advancement in the fight against hepatitis C, offering hope to those affected by the virus.
ABT-450, a New Regimen for Treating Hepatitis C Virus
ABT-450, a New Regimen for Treating Hepatitis C Virus
On April 12, 2014, the New England Journal of Medicine (NEJM) published the results of a study on the effectiveness of ABT-450/r, a new drug combination to treat patients with chronic hepatitis C virus (HCV) infection. The study, which was funded by pharmaceutical manufacturer AbbVie, was presented at the annual meeting of the European Association for the Study of the Liver in London on April 9-13, 2014.
According to the NEJM, “184 million people worldwide have chronic hepatitis C virus infection, and more than 350,000 people die of HCV-related liver disease each year.”
Adverse effects of ABT-450 most commonly were fatigue and headache. Researchers found that ABT-459 cured more than 95 percent of the patients infected with hepatitis C. ABT-450 is in pill form and takes just three 3 months to work. As of June 2014, the U.S. Food and Drug Administration had granted priority review to AbbVie's all-oral regimen for the treatment of adult patients with HCV infection, setting up possible approval before the end of the year.